Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, February 1, 2022

Some antihypertensives may reduce risk for cognitive decline

 Clear as mud, first you have to know the popular names for the classes they are referring to, then you have to know the type. So ask your doctor for clarification.

Some antihypertensives may reduce risk for cognitive decline

Certain antihypertensive medications may help prevent cognitive decline, according to results of a cohort study published in JAMA Network Open.

“Although use of antihypertensive medications that stimulate (angiotensin II receptor type 1 blockers, dihydropyridine calcium channel blockers and thiazide diuretics) vs. inhibit (angiotensin-converting enzyme [ACE] inhibitors, beta-blockers and nondihydropyridine calcium channel blockers) type 2 and 4 angiotensin II receptors has been associated with lower risk of dementia, their association with cognitive outcomes in hypertension trials, with BP levels in the range of current guidelines, has not been evaluated,” Zachary A. Marcum, PharmD, PhD, associate professor in the department of pharmacy at the University of Washington, and colleagues wrote. “Examining this question in the context of contemporary BP levels can provide clinically relevant insights into antihypertensive associations with adjudicated cognitive outcomes, independent of their BP-lowering effects.

doctor checking blood pressure
Source: Adobe Stock

“Thus, we assessed the association of prevalent use of antihypertensive regimens that exclusively contain medications that stimulate vs. inhibit type 2 and 4 angiotensin II receptors on MCI or probable dementia in the Systolic Blood Pressure Intervention Trial (SPRINT),” they added.

Marcum and colleagues conducted the secondary analysis of individuals aged 50 years or older with hypertension and increased cardiovascular risk but no history of diabetes, stroke or dementia who participated in the randomized SPRINT Trial. As the exposure, they examined prevalent use of angiotensin II receptor type 2 and 4-stimulating or -inhibiting antihypertensive medication regimens at 6 months. A composite of adjudicated amnestic mild cognitive impairment or probable dementia served as the primary outcome.

A total of 8,685 participants prevalently used antihypertensive medication regimens at 6 months (mean age, 67.7 years; 64.3% men), of whom 2,644 (30.4%) used exclusively stimulating, 1,536 (17.7%) inhibiting and 4,505 (51.9%) mixed antihypertensive medication regimes.

Across a median of 4.8 years of follow-up, Marcum and colleagues noted 45 vs. 59 cases per 1,000 person-years of amnestic mild cognitive impairment or probable dementia among prevalent users of regimens featuring exclusively stimulating vs. inhibiting antihypertensive medications (HR = 0.76; 95% CI, 0.66-0.87). When they compared stimulating-only with inhibiting-only users, they found amnestic mild cognitive impairment rates of 40 vs. 54 cases per 1,000 person-years (HR = 0.74; 95% CI, 0.64-0.87) and probable dementia rates of eight vs. 10 cases per 1,000 person-years (HR = 0.8; 95% CI, 0.57-1.14). Further, they noted residual confounding, according to results of negative control outcome analyses.

 

No comments:

Post a Comment